Resmetirom is a small molecule commercialized by Madrigal Pharmaceuticals, with a leading Pre-Registration program in Non-Alcoholic Steatohepatitis (NASH). According to Globaldata, it is involved in 16 clinical trials, of which 12 were completed, and 4 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Resmetirom’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Resmetirom is expected to reach an annual total of $3.06 bn by 2032 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Resmetirom (MGL-3196, VIA-3196, THR-Beta agonist 3196) is under development for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis. The therapeutic candidate is formulated as tablet and orally administered. The therapeutic candidate acts by targeting beta-selective thyroid hormone receptor.
It was also under development for the treatment of heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH).
Madrigal Pharmaceuticals Overview
Madrigal Pharmaceuticals (Madrigal), formerly Synta Pharmaceuticals Corp, is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel drugs for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, resmetirom (MGL-3196), is a proprietary, liver-directed, selective thyroid hormone receptor beta (THR-beta) agonist that can potentially help treat several diseases with high unmet medical need. The company is developing resmetirom for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), associated dyslipidemias and familial hypercholesterolemia (FH). The company is also developing MGL-3745 (THR-beta agonist), a preclinical compound that has thyroid receptor selectivity similar to that of MGL-3196. Madrigal is headquartered in West Conshohocken, Pennsylvania, the US.
The operating loss of the company was US$293.6 million in FY2022, compared to an operating loss of US$242.5 million in FY2021. The net loss of the company was US$295.4 million in FY2022, compared to a net loss of US$241.9 million in FY2021.
For a complete picture of Resmetirom’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.